Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
J Headache Pain
.
2022 Dec 19;23(1):161.
doi: 10.1186/s10194-022-01530-9.
Authors
Andreas R Gantenbein
1
,
Reto Agosti
2
,
Christian P Kamm
3
4
,
Gunther Landmann
5
,
Niklaus Meier
6
,
Gabriele Susanne Merki-Feld
7
,
Jens A Petersen
8
,
Heiko Pohl
9
,
Philippe Ryvlin
10
,
Christoph J Schankin
3
,
Dragana Viceic
11
,
Chiara Zecca
12
13
,
Elisabeth Schäfer
14
,
Ina Meyer
15
,
Michael E Arzt
15
Affiliations
1
Department of Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland.
[email protected]
.
2
Kopfwehzentrum Hirslanden, Zurich, Switzerland.
3
Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland.
4
Neurocentre, Luzerner Kantonsspital, Lucerne, Switzerland.
5
Center for Pain Medicine, Nottwil, Switzerland.
6
Department of Neurology, Spital Thun, Thun, Switzerland.
7
Department of Reproductive Endocrinology, University Hospital Zurich, Zurich, Switzerland.
8
Neurozentrum Bern, Bern, Switzerland.
9
Department of Neurology, University Hospital Zurich, Zurich, Switzerland.
10
Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland.
11
Private Practice, Sion, Switzerland.
12
Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
13
Faculty of Biomedical Sciences, Università Della Svizzera Italiana, Lugano, Switzerland.
14
Department of Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland.
15
Novartis Pharma Schweiz AG, Rotkreuz, Switzerland.
PMID:
36536271
PMCID:
PMC9764682
DOI:
10.1186/s10194-022-01530-9
No abstract available
Publication types
Published Erratum